Immunomedics Analyst Says Trodelvy Likely To Capture 50% Market Share

Immunomedics, Inc. IMMU stock, which has been on a broader upward trajectory since FDA approved its lead asset Trodelvy, has further room to run, according to a Jefferies analyst. 

The Immunomedics Analyst: Chris Howerton reiterated a Buy rating on Immunomedics and increased the price target from $41 to $55.

The Immunomedics Thesis: After a long wait, Immunomedics now has a commercial product in Trodelvy, which received the FDA nod for treating metastatic, triple-negative breast cancer in late April, Howerton said in a Monday note. (See his track record here.)

Following a volatile period for the stock over the last year, investors are now focused on the strength of Trodelvy's launch; potential label expansion in earlier lines of therapy and other indications; any further pipeline opportunities; and speculation on M&A, the analyst said.

Trodelvy is in the middle of a strong launch, Howerton said, citing a Jefferies survey of 50 U.S.-based medical oncologists regarding Trodelvy awareness and prescribing habits, as well as an attempt to predict trends over the next 12 months. The analyst said he expects the trend to continue.

Jefferies' revised price target factors in a faster ramp in penetration rates during the early stages of the launch, an increase in both prescription compliance rates and year-over-year price increase. 

The awareness level among the oncologist community is high, and utilization appears to be over 90% after about three months on the market, Howerton said. 

Physicians showed a willingness to prescribe Trodelvy in earlier lines despite its label for third-line+ setting, the analyst said.

Access and reimbursement appears to be seamless in the early stages of launch, he said.

"While utilization and penetration rates are already relatively high, our regression analysis suggests this momentum to grow, achieving ~40-50% market share in 3L mTNBC patients over this first year."

IMMU Price Action: Immunomedics shares were trading 4.2% higher at $42.94 at last check Monday. 

Related Links:

The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings

Pfizer Analyst Says COVID-19-Driven Rally Not Backed By Vaccine Economics

Posted In: Chris HowertonJefferiesAnalyst ColorHealth CarePrice TargetReiterationAnalyst RatingsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.